Re: value
I have a great idea. lets speak today if possible please note
The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved
please note
The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved
please note
The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved
EFTA00995807
co formed not we have to invest
This is a series of email exchanges. Key entities are:
- Jeffrey E. (from "jeevacation@gmail.com")
- George Church (recipient in some emails, sender in others)
- Darren Indyke (copied on one email)
Key topics discussed include:
- Forming and getting documents for an investment.
- Potential company names/ventures: Revenesis.com, Transvenesis.com, Georgarage.com.
- Discussions about "Bio-nano-info" and "Genetically Engineered Organisms".
- Checking with eGenesisBio.com and "Next generation pathology" teams.
- Initiating the first investment.
EFTA00995805
Below is a first pass list of potential investments for the S1OM. This may be more information than you wanted at this point (especially given the trade-off between jargon and brevity), but I'm having so much fun, I just wanted to share it. I'm also recording a few extra thoughts, in case they provide "teaching moment" or post-mortem at some point.
| $200,000 | Supercentenarianstudy.com |
|---|---|
| $1,500,000 | eGenesisBio.com |
| $1,000,000 | Sensor-Selectors |
| $1,000,000 | Protein stability & virus resistance |
| $1,000,000 | Pest control |
| $800,000 | Aging reversal |
| $1,550,000 | Next generation pathology |
| $250,000 | Space Genetics |
| $200,000 | Cold-resistant elephants |
| $2,500,000 | 2nd tranche |
| $10,000,000 | Total |
I) Swercentenarianstudy.com Thirty genomes collected so far on a small budget by James Clement. 5200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented.
eGenesisBio.com: Using CRISPR to engineer animals for resistance to infectious diseases and to act as transplantation donors for major organs (initially kidneys) to humans. Co-founded with Prashant Mali and Luhan Yang. Already has a couple of contracts and a some rented lab space.
Sensor-selector technology for optimizing commercial production of (bio)chemicals. Lead by Vatsan Raman.
New redox-insensitive protein cross linking based on radically recoiled bacterial genomes and/or Multi-virus-resistant organisms. We just published papers and patents on this. Lead by Dan Mandell.
Eliminating ecosystem pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs.
Making human genetic disease models in organoids and aging reversal using CRISPR and other epigenetic reprogramming factors. Lead by Bobby Dhadwar and Eswar lyer. Possibly mergeable with Supercentenarianstudy.com
A new sequencing method capable of displacing part of the medical pathology imaging market and filling in the large gaps in most plant and animal genome sequences. Lead by Rich Terry.
Genome engineering of humans for space. Seed money for patent fees, some lab tests and education efforts via pgEd. Lead by Ting Wu.
Making cold-resistant elephants via CRISPR, focusing on blood, subcutaneous fat and wool/hair (based on what is know about cold-resistant animals, Mammoth DNA, and human mutations). Economics could be like the American Bison which recently grew from a hundred to 500,000 as a source of low cholesterol meat. Lead by Margo Monroe and Justin Quinn. Possibly mergeable with EgenesisBio.
The rest would be set aside as a second tranche for whichever of the above efforts makes best progress first.
--George
EFTA00995806